Picture of AbCellera Biologics logo

ABCL — AbCellera Biologics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

AbCellera Biologics Q3 revenue smashes estimates

Overview

AbCellera Q3 2025 revenue rises to $9 mln, beating analyst expectations

Net loss widens to $57.1 mln, driven by higher R&D expenses

Company advances two lead programs through Phase 1 clinical trials

Result Drivers

R&D INVESTMENTS - Increased R&D expenses focused on internal programs, including $15 mln investment in two lead programs

LIQUIDITY MANAGEMENT - Maintained $680 mln in available liquidity to support strategic execution

Key Details

MetricBeat/MissActualConsensus Estimate
Q3 RevenueBeat$9 mln$5.91 mln (8 Analysts)
Q3 Net Income-$57.10 mln
Analyst Coverage The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell" The average consensus recommendation for the biotechnology & medical research peer group is "buy" Wall Street's median 12-month price target for Abcellera Biologics Inc is $8.50, about 44.8% above its November 5 closing price of $4.69 Press Release: ID:nBw6KWm87a For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on AbCellera Biologics

See all news